{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"176","value":"676"},{"groupId":"OG001","spread":"158","value":"634"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"acMMAE: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"129","value":"697"},{"groupId":"OG001","spread":"138","value":"694"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"acMMAE: Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"159","value":"763"},{"groupId":"OG001","spread":"107","value":"759"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"acMMAE: Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.57","value":"34.3"},{"groupId":"OG001","spread":"9.42","value":"37.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Total Ab: Cycle 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.00","value":"36.6"},{"groupId":"OG001","spread":"9.46","value":"40.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Total Ab: Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"9.98","value":"41.3"},{"groupId":"OG001","spread":"5.06","value":"44.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Total Ab: Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.00","value":"3.31"},{"groupId":"OG001","spread":"1.34","value":"2.21"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"title":"Unconjugated MMAE: Cycle 1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Unconjugated MMAE: Cycle 2"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Unconjugated MMAE: Cycle 4"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Bendamustine: Cycle 1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Bendamustine: Cycle 2"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Bendamustine: Cycle 4"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Rituximab: Cycle 1"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Rituximab: Cycle 2"},{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"Rituximab: Cycle 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.","dispersionType":"Standard Deviation","groups":[{"description":"Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG000","title":"Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL"},{"description":"Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG001","title":"Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL"}],"paramType":"MEAN","populationDescription":"PK evaluable population included all the ITT participants in Cohort 1a (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Cmax was not evaluated for Bendamustine and Rituximab.","reportingStatus":"POSTED","timeFrame":"Cycles 1, 2 and 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)","title":"Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a","type":"SECONDARY","unitOfMeasure":"ng/mL"}